Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28521553 | 0.88 | APP (0.40) | BACE1IRAK4KCNH2APP | |
| SCHEMBL20436541 | 0.84 | BACE1 (0.34) | BACE1IRAK4KCNH2 | |
| SCHEMBL11915102 | 0.83 | BACE1 (0.33) | BACE1IRAK4KCNH2 | |
| SCHEMBL20436539 | 0.82 | CACNA1C (0.41) | BACE1IRAK4KCNH2APP | |
| SCHEMBL20436543 | 0.81 | MEN1 (0.37) | BACE1IRAK4KCNH2 | |
| SCHEMBL4505482 | 0.78 | PDE5A (0.42) | BACE1 | |
| SCHEMBL379113 | 0.78 | KCNH2 (0.38) | BACE1IRAK4KCNH2 | |
| SCHEMBL537628 | 0.78 | MBOAT4 (0.38) | BACE1IRAK4KCNH2 | |
| SCHEMBL29994742 | 0.78 | KCNH2 (0.38) | BACE1IRAK4KCNH2 | |
| SCHEMBL20416633 | 0.77 | BACE1 (0.37) | BACE1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577367-B2 | IRAK4 inhibiting agents | BIOGEN MA INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | BIOGEN MA INC. | 2019-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248787-A1 | IRAK4 INHIBITING AGENTS | IRAK4, IRAK1, IRAK2 | BACE1 3533/4885IRAK4 1/4885KCNH2 4688/4885 |
| US-10577367-B2 | IRAK4 inhibiting agents | IRAK4, IRAK1, IRAK2 | BACE1 3533/4885IRAK4 1/4885KCNH2 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.